myriamed is now a member of the Network for Pharma Solutions
About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in the controlling of their fate as to the differentiation into defined cellular lineages and tissues (published for example in Tiburcy et al. 2017 and Long et al. 2018). The myriamed product portfolio is constantly evolving and based on a comprehensive IP portfolio to offer its know-how and associated services in drug development.
To learn more about myrPlates and myriamed’s other products please contact us on:
About NetPhaSol: NetPhaSol is a cooperation network of more than 50 innovative companies and research institutes. The primary focus are the first value chain stages of a drug development cycle - however, further development stages are not excluded.
The network offers an attractive performance portfolio in the fields of e.g. drug discovery, target validation, lead optimization and drug targeting to potential customers, partners and investors for participation and cooperation. The portfolio does not only represent the development of its own products and services and their marketing, but should also be attractive to potential customers of contract research or development.
To learn more about NetPhaSol please visit:
Tel.: +49 551 28878-170
myriamed – the drug development accelerator
Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.
The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.
At myriamed we focus on heart and skeletal muscle as well as on neuronal organoids. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle as well as on neuronal organoids.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release myriamed is now a member of the Network for Pharma Solutions here
News-ID: 2221483 • Views: 337
More Releases from myriamed GmbH
myriamed has joined Science Exchange
Science Exchange, the leading SaaS-enabled marketplace platform for outsourced R&D services, has partnered with myriamed. Visit myriamed’s profile to inquire about our services or request a quote. There are no additional contracts required if you request on Science Exchange and you can order immediately. Please visit our profile here: http://bit.ly/myriamed_Science_Exchange About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and
Helping to accelerate the development of novel drugs against Covid-19 disease
Even though vaccines against Covid-19 will be available soon, artificial herd immunity via vaccination will probably not reached until the end of 2021. Thus, the current fight against Covid-19 disease heavily relies on already available drugs. Unfortunately, there is hardly any drug that fights the disease effectively. Cortisone based therapeutics are currently the ones used most frequently and most successfully. The originally promising drug Remdesivir, which has been approved for the
myriamed’s myrPlates are now also available from ZAGENO
We are proud to announce that myriamed’s myrPlates are now also available in the ZAGENO life science, e-commerce marketplace. myrPlates can be used for the generation of engineered human tissues. By parallel culture of up to 48 tissues in one myrPlate, e.g. contractile heart muscles or skeletal muscles can be obtained to serve numerous applications, such as drug screening and disease modelling. About myriamed: myriamed has unique expertise in research and development
Generation of Engineered Human Myocardium using myriamed myrPlates
In STAR Protocols Tibury et al. describe a robust method for the generation of engineered human myocardium (EHM) from pluripotent stem cells (PSCs) in 48 well myriamed myrPlates under defined, serum-free conditions (DOI: 10.1016/j.xpro.2020.100032). By parallel culture of up to 48 EHM in one myrPlate, contractile heart muscle can be obtained to serve numerous applications, such as drug screening and disease modelling, which are also offered by myriamed. The described protocol has